ftc report pharmacy benefit managers

Pharmacy benefit managers inflated drug prices by $7.3B

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Reuters · 1d

US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.

Campus Safety Magazine · 3h

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts

2hon MSN

UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...

MedCity News11h

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

policymed.com1d

Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics

The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Pharmacy benefit managers inflated drug prices by $7.3B

Trending now